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Abstract 
Purpose: To compare carbon-ion beam dose distribution between passive and scanning 
radiation therapies for locally advanced pancreatic cancer.  
 
Materials and Methods: Thirteen pancreatic cancer patients were included in this study. 
Four types of treatment planning with respiratory gating were calculated for each 
patient: a four-field box with passive irradiation (Plan 1), scanning irradiation (Plan 2), 
a three-field (150°, 180° and 210°) protocol with passive irradiation (Plan 3), and 
scanning irradiation (Plan 4). The irradiation plans each delivered 55.2 Gy(RBE) to the 
planning target volume (PTV) and were compared with respect to doses to the PTV and 
organs at risk (OARs).  
 
Results:  Plan 3 exceeded the dose assessment metrics to the spinal cord. Scanning 
irradiation plans (Plan 2 and, particularly, Plan 4) offered significantly reduced dosage 
to the stomach and the duodenum compared with passive irradiation.  
 
Conclusion:  Three-field oblique scanning irradiation for pancreatic cancer has the 
potential to reduce gastrointestinal exposure and influence of peristalsis on dose 
distribution. 
 
Keywords: Carbon-Ion Radiotherapy, Pancreatic Cancer, Radiation Dosimetry  
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INTRODUCTION 
Pancreatic cancer accounted for an estimated 46,420 cancer cases and 39,590 cancer 
deaths worldwide in 2014 [1]. Selected patients may be curable when treated with 
high-dose chemoradiotherapy, but delivery of high-dose radiation is limited owing to 
the proximity of organs at risk (OARs). Several dosimetric studies have reported that 
proton therapy improves the dose-volume histograms (DVHs) over conventional 
photon therapy and intensity-modulated radiation therapy (IMRT) by reducing 
excessive doses to normal  tissues [2, 3]. Carbon-ion beams provide a sharp lateral 
penumbra and narrow Bragg peak compared to proton beams  [4], and demonstrate 
increased relative biological effectiveness (RBE).  
Our carbon-ion beam therapy center was constructed in 1994, and has provided 
treatment to more than 9,000 cancer patients [5]. Since, a constant spread-out Bragg 
peak (SOBP) over the beam field in a passive irradiation system can cause undesirable 
doses to normal tissues at the beam entry side of the target , dose escalation can be 
limited by the risk of gastrointestinal side effects. T he scanning delivery system was 
developed to avoid these issues . Our facility began providing scanning irradiation 
without respiratory gating in 2011, with good clinical result s [6]. 
We have clinical experience with four-field box treatments for pancreatic cancer 
using passive irradiation. Before starting pancreatic scanning irradiation, it is 
necessary to evaluate dose distributions between passive and scanning irradiation 
techniques. Here, we compared dose distributions among irradiation techniques using 
treatment planning software.  
 
 
MATERIALS AND METHODS 
Between November 2013 and February 2014, 13 patients were randomly selected from 
among patients with inoperable pancreatic cancer who underwent four -field box 
passive irradiation at our hospital. The characteristics of the enrolled patients are listed 
in Table 1. The patients were positioned in customized cradles (Moldcare®, Alcare, 
Tokyo, Japan) and immobilized with a low-temperature thermoplastic shell 
(Shellfitter®, Kuraray, Osaka, Japan). Treatment planning CT was acquired in 
four-dimensional (4D) mode under free breathing conditions (Aquilion One Vision 
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Edition®, Toshiba Medical Systems, Otawara, Japan).  The study was approved by the 
institutional review boards of our institutions and participating patients gave informed 
consent. 
  
Treatment planning  
Tumor extent was evaluated by CT, magnetic resonance imaging (MRI), and positron 
emission tomography (PET).  A radiation oncologist manually delineated the gross 
tumor volume (GTV) and OARs on the CT images at peak exhale . Clinical target 
volume (CTV) was defined as the GTV plus a 5 mm margin plus locoregional lymph 
nodes and neural plexus regions. Planning target volume (PTV) was defined as the 
CTV with an added margin of at least 5 mm in all directions, modified if OARs were 
close to the GTV. The gating window was generally defined as a 30% duty cycle around 
the exhale phase. The mean (± standard deviation) GTV displacement at 30% of 
exhalation for all patients was 2.5 mm (± 1.6 mm) in the anterior-posterior direction, 
2.1 mm (± 1.0 mm) in the lateral direction, and 2.5 mm (± 1.6 mm) in the 
superior-inferior direction. The internal target volume (ITV) was calculated by adding 
the internal margin derived from 4DCT to the CTV.  
Four respiratory-gated treatment plans were generated: a four-field box with passive 
irradiation (Plan 1) (our present standard technique),  four-field scanning irradiation 
(Plan 2), a three-field (150˚, 180˚, and 210˚) protocol with passive irradiation (Plan 3),  
and three-field scanning irradiation (Plan 4) . The Plan 1 and Plan 2 treatment fraction 
schemes used three fractions at 0 ˚, two fractions at 90˚, four fractions at 180˚, and 
three fractions at 270˚. The Plan 3 and Plan 4 scheme used four fractions each at 150 ˚ , 
180˚ and 210˚. The carbon-ion dose for each plan totaled 55.2 Gy(RBE) in 12 fractions 
[7]. A patient collimator to reduce blurring of lateral dose distribution was 
manufactured for each field in passive irradiation, but is not required in scanning 
irradiation. 
Doses were evaluated with regard to dose delivered to 95% of PTV (PTV-D95), dose 
to the most exposed 2 cc (D2cc) and volume receiving > n Gy(RBE) (Vn Gy(RBE)) of 
the stomach, duodenum (D1-2: 1
st
 and 2
nd
 portions, D3-4: 3
rd
 and 4
th
 portions) and 
kidneys, and the maximum dose (Dmax) to the spinal cord. Treatment planning was 
performed to cover the PTV-D95 with at least 90% of the prescribed dose. The dose 
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constraints were as follows: 50% of the kidneys’ volume should receive <  15 Gy(RBE), 
a V30 of stomach/D1-2/D3-4 < 5 cc, and a D2cc of the stomach/D1-2/D3-4 < 40 
Gy(RBE). The dose to the spinal cord was limited to 30 Gy (RBE). The dose 
constraints of the OARs were assigned higher priority than target dose coverage. Dose 
assessment metrics in the respective plans were compared using t he Wilcoxon 
signed-rank test. All p values were two-sided and those < 0.05 were regarded as 
statistically significant.  
 
  
RESULTS 
A typical dose distribution and DVH for each plan are shown in Figures 1 and 2, 
respectively. For the four-field box irradiation, Plan 2 increased OAR dose in the range 
of < 5 Gy(RBE) and decreased dose in the range of ≥ 5 Gy(RBE) in comparison to Plan 
1. In Figure 1, cold spots appear in the anterior side of the PTV in Plan 2, because the 
stomach was cephalad to the PTV; however, it was still at a clinically acceptable level 
(Plan 1/Plan 2 PTV-D95, 51.6 Gy(RBE)/51.3 Gy(RBE)). For the oblique beam angles, 
Plan 3 and Plan 4 decreased the dose to the intestinal tract in the range of 10%, but 
also increased the dose to the spinal cord, kidneys, and vertebral bodies in the range of 
10–70%. The dose to the cord exceeded the maximum tolerated dose in Plan 3 (Plan 
3/Plan 4 spinal cord Dmax, 51.2 Gy(RBE)/29.7 Gy(RBE); right kidney V10, 113.9 
cc/48.1 cc; left kidney V10, 15.1 cc/4.6 cc). The skin dose in Plan 3 was higher than 
that in Plan 4.  
For all the patients, the D95 in all plans was over 90% of the prescribed dose to the 
PTV (= 49.68 Gy(RBE)) (Table 2). The Plan 3 data were excluded from analysis 
because all cases in Plan 3 exceeded the maximum allowed dose to the spinal cord. We 
compared the results for Plans 1, 2, and 4.  
Comparing Plan 1 with Plan 2, the PTV coverage remained at a similar level. Plan 2 
decreased the V10 of the stomach and duodenum (Plan 1/Plan 2 stomach V10, 88.9 
cc/33.9 cc; D1-2 V10, 27.7 cc/12.6 cc; D3-4 V10, 8.1 cc/4.4 cc). Although the V20 of 
D1-2 was higher in Plan 2, the difference in values was very small and would be 
clinically insignificant (D1-2 V20, 0.4 cc/0.7 cc). Excepting the D1-2 V20, there was 
no difference in range of ≥ V20 or V30 to the stomach and duode num. Dmax to the 
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spinal cord in Plan 2 was lower than that in Plan 1 (Dmax, 18.4 Gy(RBE)/12.3 
Gy(RBE)). Plan 2 decreased the dose to both kidneys (right kidney V10, 8.4 cc/0.1 cc; 
left kidney V10, 25.6 cc/14.2 cc).  
As described above, Plan 2 was superior to Plan 1, and Plan 3 resulted in an 
overdose to the spinal cord. Accordingly, we compared scanning irradiation techniques 
using Plans 2 and 4. Both plans achieved adequate PTV coverage. Although there were 
no differences in any range of D3-4 or in the range of ≥  V20 of D1-2, Plan 4 decreased 
D2cc, V20 and V10 to the stomach and V10 to D1-2 (Plan 2/Plan 4 stomach D2cc, 23.1 
cc/19.5 cc; V20, 3.1 cc/1.9 cc; V10, 33.9 cc/6.4 cc; D1-2 V10, 12.6 cc/2.2 cc). Dmax 
to the spinal cord and doses to both kidneys in Plan 4 were higher than those in Plan 2 
due to the beam angles, although they remained within an acceptable range.  
 
 
DISCUSSION 
We assessed carbon-ion beam dose planning distributions for pancreatic cancer by 
comparing passive and scanning irradiation, and four -field box and oblique three-field 
beam angles. Irrespective of beam angle,  scanning irradiation resulted in lower doses 
to the stomach and duodenum, because scanning irradiation minimizes excessive dose 
to the normal tissues in front of the target.  
The stomach and duodenum received less excessive doses from the passive 
irradiation in the range of < 5 Gy(RBE) (Figure 2), because the patient collimator used 
in passive irradiation reduced lateral dose fall -off. 
Dose escalation for pancreatic cancer  has been studied clinically [8, 9]. The main 
limiting adverse effect has been upper gastrointestinal toxicity [10]. Tseng et al. 
assumed that low doses to the stomach were the only significant dosimetric variables 
correlating with the development of nausea, vomiting, or both. A stomach V10 ≥ 11.5% 
was the best predictor. In their s tudy, the total proton radiotherapy dose was 25 
Gy(RBE) in 5 fractions [11]. Conversely, Nakamura et al. reported that high, rather 
than low, doses to the stomach caused complications. A V50 ≥ 16 cc and V50 ≥ 33 cc 
were particularly the best predictors of grade 2 or higher acute gastr ointestinal tract 
and upper gastrointestinal bleeding, respectively. In their study, t he total photon 
radiotherapy dose was 54 Gy in 30 fractions [12]. The dosimetric parameters of 
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gastrointestinal toxicity are controversial, but the dose to the upper gastrointestinal 
tract in our present study was below the doses reported in these studies. In our institute, 
Shinoto et al. reported that when the dose levels of carbon ion radiotherapy were 
escalated from 43.2 to 55.2 Gy (RBE) in 12 fractions, only 1 of the 72 treated patients 
experienced a late grade 3 gastric ulcer and bleeding [13]. 
Gas and peristalsis in the gastrointestinal tract can cause dose distribution variations. 
Kumagai et al. reported that  beam angles in the anterior and left directions could be 
associated with dose variations due to gas bubble positions, resulting in beam 
overshoot/undershoot [14]. To solve this problem, it is recommended to irradiate 
through solid organs, such as the spinal cord and kidneys. Although Plan 3 led to 
overdose to OARs, Plan 4 met the criteria. Our results indicate that scanning 
irradiation enables therapy which is less subject to dose irregularities from gas in the 
digestive tract. 
It is reported that intensity-modulated proton therapy (IMPT) has potential 
advantages in conformity of target coverage and better sparing of normal tissue. 
Though IMPT may reduce the normal tissue dose and allow further dose escalation 
compared to IMRT or passive scattering proton therapy [15], additional studies are 
required because of the risk of multiple inhomogeneous fields due to intra - and 
inter-fraction motion [16]. 
Several limitations of our study warrant mention.  First, we did not use a 
field-specific ITV, which considers intrafractional range variations, in this study. This 
is because most commercial treatment planning systems have n ot yet implemented the 
design function of the field-specific ITV. Our pancreatic treatment was applied with 
respiratory gating to minimize intrafractional motion and 3D treatment planning was 
not problematic in this study.  
Second, we calculated dose distribution using CT images acquired in the supine 
position only, whereas in practice CT images are acquired in both the supine and prone 
positions. There is a significant reduction in the movement of the liver and pancreas in 
the prone position, especially in the superior–inferior direction [17]. The prone 
position may offer an advantage in radiotherapy in these organs. 
Finally, several groups have reported that the interplay effect of residual target 
motion can still lead to significant underdosing and thus requires further mitigation 
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techniques such as rescanning, even though gating is applied. Treatment p lanning 
would be more realistic when dose distributions are calculated at different respiratory 
phases with inclusion of the interplay effect (full 4D treatment planning), however, 
most commercially available treatment planning system cannot do this. Previ ously, our 
group reported that four or more phase-controlled rescannings should substantially 
improve the accuracy of dose conformation [18, 19]. Therefore, we did not consider the 
interplay effect in this study.  
 
CONCLUSIONS 
We found that an oblique three-field scanning irradiation technique was superior to 
four-field box passive and four-field scanning irradiation. We believe that our results 
will be helpful for the planning of respiratory-gated scanning irradiation and 
dose-escalation trials for pancreatic cancer. 
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Table 1 
Patient characteristics.  
UICC Stage grouping: Stage IIA: T3, N0, M0; Stage III: T4, Any N, M0; Stage IV: Any 
T, Any N, M1 
 
  
  Characteristics
Number of patients 13
Age, years
Median ( range ) 63 ( 35 - 80)  
Gender
Male 8
Female 5
PS
0 12
1 1
ⅡA 2
Ⅲ 8
Ⅳ 3
Tumor location
Head 6
Body/tail 7
GTV size, cc
Median ( range ) 13.9 ( 1.7 -47.4 )
CA19-9, U/ml
Median ( range ) 684.5 ( 0.1 - 6560 )
Stage ( UICC 7th ）
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Table 2 
Dose assessment for all patients.  
Abbreviations: PTV, planning target volume; D95, dose delivered to 95% of the 
irradiated volume; Dmax, maximum dose; Vn, volume receiving > n Gy(RBE); D1-2, 
1
st
 and 2
nd
 portions of duodenum; D3-4, 3
rd
 and 4
th
 portions of duodenum; P 1, Plan 1; 
P 2, Plan 2; P 4, Plan 4; range*, interquartile range.   
 
  
P 1 vs P 2 P 2 vs P 4
median ( range* ) median ( range*) median ( range* ) median ( range* ) p values p values
PTV
D95, Gy (RBE) 51.8 (51.6-52.2) 51.3 (51.3-51.5) 51.8 (51.2-51.9) 51.4 (51.2-52.0) 0.16 0.95
Stomach
D2cc, Gy (RBE) 25.2 (19.9-28.8) 23.1 (21.0-27.5) 8.9 (8.2-16.9) 19.5 (18.1-24.7) 0.67 <0.01
V30, cc 0.3 (0.2-1.6) 0.6 (0.5-1.4) 0.0 (0.0-0.2) 0.7 (0.4-1.2) 0.20 0.75
V20, cc 4.8 (2.0-14.9) 3.1 (2.4-5.5) 0.2 (0.1-1.3) 1.9 (1.7-3.2) 0.07 <0.01
V10, cc 88.9 (71.6-112.0) 33.9 (20.7-38.0) 3.2 (0.8-3.8) 6.4 (4.8-8.3) <0.01 <0.01
D1-2
D2cc, Gy (RBE) 15.9 (15.4-19.3) 12.2 (10.9-15.9) 19.0 (2.6-19.5) 15.6 (8.3-19.4) 0.05 0.46
V30, cc 0.1 (0.0-0.5) 0.2 (0.0-0.7) 0.0 (0.0-0.3) 0.1 (0.1-0.7) 0.07 0.81
V20, cc 0.4 (0.1-1.8) 0.7 (0.3-2.1) 1.1 (0.3-2.5) 0.9 (0.4-1.9) <0.01 0.38
V10, cc 27.7 (22.8-31.0) 12.6 (9.5-15.8) 6.0 (0.9-9.5) 2.2 (1.3-7.2) <0.01 <0.01
D3-4
D2cc, Gy (RBE) 13.3 (9.8-23.6) 17.2 (11.7-20.9) 9.0 (2.1-21.6) 13.2 (11.4-20.3) 0.72 0.14
V30, cc 0.2 (0.1-0.7) 0.6 (0.3-0.8) 0.2 (0.0-0.9) 0.6 (0.1-1.0) 0.05 0.73
V20, cc 1.4 (0.4-2.7) 1.5 (0.9-2.2) 0.6 (0.3-2.3) 1.3 (0.7-2.0) 0.75 0.36
V10, cc 8.1 (1.9-14.0) 4.4 (2.3-6.1) 2.1 (0.8-4.5) 3.1 (2.3-8.4) <0.05 0.29
Spinal cord
Dmax, Gy (RBE) 18.4 (16.7-19.8) 12.3 (11.7-13.0) 51.2 (47.3-52.6) 27.9 (26.9-28.7) <0.01 <0.01
Rt kidney
D2cc, Gy (RBE) 14.6 (8.0-20.0) 8.7 (4.3-15.5) 17.2 (13.3-27.2) 11.0 (9.5-28.2) <0.01 <0.01
V30, cc 0.0 (0.0-0.2) 0.0 (0.0-0.4) 0.0 (0.0-0.2) 0.0 (0.0-1.4) 0.31 0.05
V20, cc 0.0 (0.0-2.0) 0.0 (0.0-1.2) 0.0 (0.0-4.6) 0.0 (0.0-10.5) 0.22 0.05
V10, cc 8.4 (1.6-17.6) 0.1 (0.0-4.8) 36.7 (21.4-94.7) 4.0 (1.1-43.1) <0.01 <0.01
Lt kidney
D2cc, Gy (RBE) 22.4 (13.6-27.0) 23.4 (11.4-25.6) 46.4 (27.4-53.3) 33.5 (21.6-38.0) 0.16 <0.01
V30, cc 0.8 (0.1-1.5) 1.0 (0.3-1.2) 12.7 (1.4-14.5) 3.2 (0.7-5.8) 0.65 <0.01
V20, cc 3.9 (0.6-11.9) 2.3 (0.8-2.6) 19.6 (4.6-25.7) 9.9 (2.7-14.8) <0.05 <0.01
V10, cc 25.6 (12.6-32.3) 14.2 (2.6-16.9) 69.9 (60.1-95.3) 37.0 (20.5-57.3) <0.01 <0.01
Plan 1 Plan 2 Plan 3 Plan 4
passive scanning passive scanning
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Figure 1  
Carbon-ion dose distributions in axial (patient no. 10) for (a) Plan 1, (b) Plan 2, (c) 
Plan 3 and (d) Plan 4.  
Red and yellow lines show gross tumor volume (GTV) and planning target volume 
(PTV), respectively. Red, yellow, pink, green, dark blue, and light blue isodose lines 
show 95%, 90%, 70%, 50%, 30%, and 10% of the prescribed dose, respectively.  
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Figure 2 
Dose-volume histograms for (a)–(b): four-field box irradiation and (c)–(d): oblique 
beam irradiation (patient  no. 10). 
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